MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463924 | Name: Rizatriptan-d6 benzoate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rizatriptan-d6 is intended for use as an internal standard for the quantification of rizatriptan by GC- or LC-MS. Rizatriptan is an agonist of the serotonin receptor 5-HT1B and 5-HT1D.

Chemical Structure

Rizatriptan-d6 benzoate
Rizatriptan-d6 benzoate
CAS#1216984-85-8 (benzoate)

Theoretical Analysis

MedKoo Cat#: 463924

Name: Rizatriptan-d6 benzoate

CAS#: 1216984-85-8 (benzoate)

Chemical Formula: C22H19D6N5O2

Exact Mass: 0.0000

Molecular Weight: 397.51

Elemental Analysis: C, 66.47; H, 7.86; N, 17.62; O, 8.05

Price and Availability

Size Price Availability Quantity
5mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1216984-85-8 (benzoate)
Synonym
Rizatriptan-d6 benzoate salt; Rizatriptan d6 benzoate salt;
IUPAC/Chemical Name
2-(5-((1H-1,2,4-triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-bis(methyl-d3)ethan-1-amine benzoate
InChi Key
JPRXYLQNJJVCMZ-TXHXQZCNSA-N
InChi Code
InChI=1S/C15H19N5.C7H6O2/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20;8-7(9)6-4-2-1-3-5-6/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3;1-5H,(H,8,9)/i1D3,2D3;
SMILES Code
OC(C1=CC=CC=C1)=O.[2H]C([2H])(N(CCC2=CNC3=CC=C(CN4C=NC=N4)C=C23)C([2H])([2H])[2H])[2H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Rizatriptan is an antagonist of 5-HT1B and 5-HT1D receptors (Kis = 4.3 and 10.1 nM, respectively). It is selective for 5-HT1B and 5-HT1D receptors over 5-HT1A receptors (Ki = 140 nM). Rizatriptan induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 90 nM). Rizatriptan (50 and 75 mg/kg) reduces head grooming, the number of oculotemporal strokes, eye blinking, and one-eye closures in a Cacna1a mutant transgenic mouse model of migraine.
In vitro activity:
To be determined
In vivo activity:
mRNA and protein levels of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model were significantly reduced upon rizatriptan treatment. Reference: Neurosci Lett. 2015 Feb 5;587:29-34. https://pubmed.ncbi.nlm.nih.gov/25524408/
Solvent mg/mL mM
Solubility
DMSO 10.0 25.16
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 397.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yao G, Han X, Hao T, Huang Q, Yu T. Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model. Neurosci Lett. 2015 Feb 5;587:29-34. doi: 10.1016/j.neulet.2014.12.021. Epub 2014 Dec 15. PMID: 25524408. 2. Fard JK, Hamzeiy H, Sattari M, Eftekhari A, Ahmadian E, Eghbal MA. Triazole rizatriptan Induces Liver Toxicity through Lysosomal/Mitochondrial Dysfunction. Drug Res (Stuttg). 2016 Sep;66(9):470-478. doi: 10.1055/s-0042-110178. Epub 2016 Jul 11. PMID: 27399851.
In vitro protocol:
To be determined
In vivo protocol:
1. Yao G, Han X, Hao T, Huang Q, Yu T. Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model. Neurosci Lett. 2015 Feb 5;587:29-34. doi: 10.1016/j.neulet.2014.12.021. Epub 2014 Dec 15. PMID: 25524408. 2. Fard JK, Hamzeiy H, Sattari M, Eftekhari A, Ahmadian E, Eghbal MA. Triazole rizatriptan Induces Liver Toxicity through Lysosomal/Mitochondrial Dysfunction. Drug Res (Stuttg). 2016 Sep;66(9):470-478. doi: 10.1055/s-0042-110178. Epub 2016 Jul 11. PMID: 27399851.
1: Drugs for Migraine. Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-160. PMID: 33434187. 2: Singh RBH, VanderPluym JH, Morrow AS, Urtecho M, Nayfeh T, Roldan VDT, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Dec. Report No.: 21-EHC009. PMID: 33411427. 3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Rizatriptan. 2020 Oct 19. PMID: 30000522. 4: Tellone V, Dragone P, Picollo R, Rosignoli MT, Garofolo F, Del Vecchio A, Calisti F, Comandini A, Donath F, Schug B, Wedemeyer RS. A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. Int J Clin Pharmacol Ther. 2020 Oct;58(10):583-594. doi: 10.5414/CP203652. PMID: 32716291. 5: Guo X, Cun D, Wan F, Bera H, Song Q, Tian X, Chen Y, Rantanen J, Yang M. Comparative assessment of in vitro/in vivo performances of orodispersible electrospun and casting films containing rizatriptan benzoate. Eur J Pharm Biopharm. 2020 Sep;154:283-289. doi: 10.1016/j.ejpb.2020.06.023. Epub 2020 Jul 4. PMID: 32634573. 6: Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-39. PMID: 32555120. 7: Siddique AS, Siddique O, Einstein M, Urtasun-Sotil E, Ligato S. Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience. World J Hepatol. 2020 May 27;12(5):207-219. doi: 10.4254/wjh.v12.i5.207. PMID: 32547688; PMCID: PMC7280859. 8: Wang G, Tan T, Liu Y, Hong P. Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials. Clin Neurol Neurosurg. 2020 Aug;195:105853. doi: 10.1016/j.clineuro.2020.105853. Epub 2020 Apr 19. PMID: 32464520. 9: Nicolas S, Nicolas D. Triptans. 2020 May 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32119394. 10: Nouri M, Rahimnejad M, Najafpour G, Moghadamnia AA. Simultaneous voltammetric determination of rizatriptan and acetaminophen using a carbon paste electrode modified with NiFe2O4 nanoparticles. Mikrochim Acta. 2020 May 7;187(6):315. doi: 10.1007/s00604-020-04290-y. PMID: 32383071. 11: Sidhu G, Patel P. Almotriptan. 2020 Apr 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31082136. 12: Chokshi A, Vaishya R, Inavolu R, Potta T. Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. Int J Pharm. 2019 Nov 25;571:118702. doi: 10.1016/j.ijpharm.2019.118702. Epub 2019 Oct 5. PMID: 31593810. 13: Tfelt-Hansen P, Messlinger K. Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect. Br J Clin Pharmacol. 2019 Nov;85(11):2487-2498. doi: 10.1111/bcp.14090. Epub 2019 Sep 4. PMID: 31389059; PMCID: PMC6848898. 14: Öztürk B, Karadaş Ö. Cerebral Hemodynamic Changes During Migraine Attacks and After Triptan Treatments. Noro Psikiyatr Ars. 2019 Feb 12;57(3):192-196. doi: 10.29399/npa.21650. PMID: 32952420; PMCID: PMC7481983. 15: Salehi S, Boddohi S. Design and optimization of kollicoat ® IR based mucoadhesive buccal film for co-delivery of rizatriptan benzoate and propranolol hydrochloride. Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:230-244. doi: 10.1016/j.msec.2018.12.036. Epub 2018 Dec 12. PMID: 30678908. 16: Sourbron J, Partoens M, Scheldeman C, Zhang Y, Lagae L, de Witte P. Drug repurposing for Dravet syndrome in scn1Lab-/- mutant zebrafish. Epilepsia. 2019 Feb;60(2):e8-e13. doi: 10.1111/epi.14647. Epub 2019 Jan 20. PMID: 30663052; PMCID: PMC6850687. 17: Barbanti P, Grazzi L, Egeo G. Pharmacotherapy for acute migraines in children and adolescents. Expert Opin Pharmacother. 2019 Mar;20(4):455-463. doi: 10.1080/14656566.2018.1552941. Epub 2018 Dec 7. PMID: 30526161. 18: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Migraine Headache Agents. 2018 Dec 10. PMID: 31643527. 19: Ramineni KK, Jakkani RK, Girgani S, Balani A, Satyanarayan S. Triptan- induced Reversible Cerebral Vasoconstriction Syndrome Presenting With Thunderclap Headache and Paraparesis. Neurologist. 2018 Sep;23(5):160-162. doi: 10.1097/NRL.0000000000000193. PMID: 30169369. 20: Gelfand AA. Pediatric and Adolescent Headache. Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1108-1136. doi: 10.1212/CON.0000000000000638. PMID: 30074552.